Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares
Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of the company's stock on April 1st for $739,950, executed under a pre-arranged trading plan. This sale reduced his direct ownership by 2.33%, bringing his total shares to 627,540. The CEO had previously made similar sales in March and February, and analysts currently hold a consensus "Buy" rating for SYRE with an average price target of $60.67.
Spyre Therapeutics (NASDAQ:SYRE) Insider Sheldon Sloan Sells 7,958 Shares
Sheldon Sloan, an insider at Spyre Therapeutics (NASDAQ:SYRE), sold 7,958 shares of the company's stock on April 1st for a total of $397,900. This transaction, executed under a pre-arranged Rule 10b5-1 trading plan, reduced his direct ownership by 50% to 7,958 shares. Despite this insider sale and a recent earnings per share miss, the stock is trading near its one-year high, and analysts maintain a consensus "Buy" rating with an average price target of $60.67.
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows Sells 7,500 Shares
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sold 7,500 shares of the company's stock on April 1st for $370,050 under a pre-arranged Rule 10b5-1 plan, reducing his stake by 7.11%. The transaction was disclosed in an SEC filing. Despite the sale, institutional investors own a significant portion of the company, and analysts have a mixed but overall "Buy" rating on SYRE, with an average target price of $60.67.
Spyre Therapeutics (SYRE) CEO sells 15,000 shares in planned trades
Spyre Therapeutics CEO Turtle Cameron reported the sale of 15,000 shares of company stock on April 1, 2026, through two separate transactions at weighted average prices of $49.20 and $49.92 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan established in June 2025. Following these sales, Cameron directly holds 627,540 shares, which includes 116,168 shares that will vest monthly through November 2026.
[Form 4] Spyre Therapeutics, Inc. Insider Trading Activity
Spyre Therapeutics, Inc.'s Chief Medical Officer, Sloan Sheldon, exercised stock options and subsequently sold 7,958 shares of common stock. This transaction, executed under a pre-arranged Rule 10b5-1 trading plan adopted in June 2025, involved exercising options at $21.66 per share and selling the shares at $50.00 per share. The filing highlights an insider trade with a net sale of 7,958 shares valued at $397,900.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. announced the grant of inducement stock options to five new non-executive employees to purchase an aggregate of 70,200 shares. These grants were approved by the independent Compensation Committee on April 1, 2026, with an exercise price of $48.90 per share, and are material to the employees' acceptance of employment with the company. The options will vest over four years, with a quarter vesting on the first anniversary and monthly thereafter, subject to continuous service.
JPMorgan Chase & Co. Has $4.63 Million Stock Holdings in Spyre Therapeutics, Inc. $SYRE
JPMorgan Chase & Co. significantly increased its stake in Spyre Therapeutics (NASDAQ:SYRE) by 483.7% in Q3, now holding 275,984 shares valued at $4.63 million. Despite substantial insider selling by the CFO and CEO totaling $1.23 million in the last 90 days, institutional investors own 80.39% of the company. Spyre Therapeutics currently has a consensus "Buy" rating from Wall Street analysts with a target price of $60.67, even though the company recently missed EPS estimates.
Spyre Therapeutics, Inc. team assembles 1,500 kits for students during annual gathering
Spyre Therapeutics, Inc. employees recently gathered for an annual event where they assembled 1,500 kits for local students as part of the company's Women's History Month initiative. The event also featured a physician panel with IBD specialists, highlighting Spyre's dedication to community involvement and advancing medical understanding. The company is simultaneously progressing its clinical efforts, with topline results for the rheumatoid arthritis sub-study of its Phase 2 SKYWAY trial expected in Q3 2026.
SYRE SEC Filings - Spyre Therapeutics 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Spyre Therapeutics (SYRE) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It highlights recent filings detailing positive Phase 1 results for SPY003, the initiation of crucial Phase 2 trials, and financial updates including equity offerings. Investors can use this platform to access and analyze regulatory disclosures enhanced with AI-powered summaries and sentiment analysis.
[144] Spyre Therapeutics, Inc. SEC Filing
This article announces an SEC Form 144 filing by Spyre Therapeutics, Inc. (SYRE) on April 1, 2026, relating to the proposed sale of securities. The filing details the sale of 7,958 shares of common stock acquired through the exercise of stock options, with an aggregate market value of $401,401.52. The transaction was facilitated by Morgan Stanley Smith Barney LLC, and the shares are expected to be sold on NASDAQ.
Spyre Therapeutics (NASDAQ:SYRE) Receives "Buy" Rating from BTIG Research
BTIG Research has reiterated a "Buy" rating for Spyre Therapeutics (NASDAQ:SYRE), setting a price target of $70, which suggests a 54% upside from its previous closing price. This aligns with a broader positive analyst sentiment, as the company holds a consensus "Buy" rating and an average price target of $60.67 from various firms. Despite recent insider share sales totaling $1.69 million and a reported EPS miss, institutional investors have been actively adjusting their positions in SYRE.
SYRE Receives Reiteration of 'Buy' Rating by BTIG | SYRE Stock N
BTIG analyst Julian Harrison has reiterated a 'Buy' rating for Spyre Therapeutics (SYRE), maintaining a price target of $70.00. This follows previous positive ratings from other analysts, including a raised price target by Stifel in March 2026. Spyre Therapeutics, a clinical-stage biotechnology company focused on inflammatory bowel disease and rheumatic diseases, has an average target price of $60.79 from 14 analysts, implying a potential upside of 33.95% from its current price.
Is Spyre Therapeutics (SYRE) Using Faster RA Trial Timelines To Redefine Its Autoimmune Strategy?
Spyre Therapeutics (SYRE) has completed recruitment for the rheumatoid arthritis (RA) sub-study of its SKYWAY Phase 2 trial of SPY072, accelerating the expected topline readout to Q3 2026. This faster timeline strengthens clinical visibility for SPY072, an extended half-life TL1A-targeting antibody, but also concentrates investment risk on the successful outcome of this single Phase 2 program given the company's lack of revenue and ongoing losses. The article suggests investors should focus on fundamental analysis and potential warning signs rather than just the accelerated trial timelines.
Vanguard disaggregates holdings for Spyre Therapeutics (SYRE); reports 0 shares
The Vanguard Group filed an Amendment No. 1 to a Schedule 13G/A, reporting 0 shares of Spyre Therapeutics Inc Common Stock. This administrative filing is due to an internal realignment effective January 12, 2026, which causes certain Vanguard subsidiaries to report their holdings separately. Vanguard Inc. no longer beneficially owns these securities, and the reported holdings include securities in the form of rights, with other subsidiaries expected to file separately.
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 5.7% - Time to Buy?
Spyre Therapeutics (NASDAQ:SYRE) saw its stock price climb 5.7% to about $48.30, trading above its 50-day and 200-day moving averages with a market cap of $3.82 billion. Despite analysts maintaining largely bullish ratings with an average price target of $60.67, the company continues to report quarterly losses, and insiders have sold a significant number of shares recently. Institutional ownership remains high at over 80%, while insiders own 15.43% of the company's stock.
Spyre Therapeutics stock hits 52-week high at 45.79 USD By Investing.com
Spyre Therapeutics has reached a 52-week stock high of $45.76, driven by a 170% surge over six months and accelerated clinical trial timelines for its therapies. Despite this success, InvestingPro data suggests the stock might be overvalued. Analyst firms have responded positively to these developments, raising price targets and reiterating strong ratings.
Spyre Therapeutics stock hits 52-week high at 45.79 USD By Investing.com
Spyre Therapeutics has reached a new 52-week high of $45.76 USD, reflecting a 170% surge in its stock over the past six months and a market capitalization of $3.56 billion. This growth is attributed to accelerated clinical trial timelines for its SPY072 and SKYLINE programs, which have garnered positive analyst ratings and raised price targets. Despite being considered overvalued by InvestingPro.
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of "Buy" from Brokerages
Spyre Therapeutics, Inc. (NASDAQ:SYRE) has an average "Buy" rating from ten brokerages, with an average one-year price target of $60.67. Insider selling by the CEO and CFO was noted, totaling 47,500 shares worth $1.69 million in the last quarter, while institutional investors hold 80.39% of the shares. The company reported an EPS of ($0.70) for the last quarter, missing consensus estimates.
Spyre Therapeutics Completes First-in-Human Study of SPY001-001, De-risking Early Pipeline
Spyre Therapeutics (SYRE) has successfully completed a Phase 1 clinical trial for its experimental drug SPY001-001, which assessed its safety, tolerability, and pharmacokinetics in healthy participants. This completion de-risks the early development pipeline for the company, even though detailed results are not yet publicly available. The trial's positive outcome could improve investor sentiment and competition for attention among small-cap biotechs, with future disclosures on safety and exposure levels expected to drive share price movements.
SYRE Technical Analysis | Trend, Signals & Chart Patterns | SPYRE THERAPEUTICS INC (NASDAQ:SYRE)
This article provides a technical analysis of SPYRE THERAPEUTICS INC (NASDAQ:SYRE), giving it an overall technical rating of 9 out of 10. Both long-term and short-term trends are positive, with the stock outperforming 95% of other stocks and 85% of its industry peers. The analysis identifies key support and resistance levels, current indicator signals, and potential setup patterns for trading, including an example entry and exit strategy.
VR Adviser Increases Spyre Therapeutics Investment to $120.74M - News and Statistics
Investment firm VR Adviser, LLC significantly increased its stake in biotechnology company Spyre Therapeutics, acquiring an additional one million shares. This boosted their total holding to 3,685,448 shares valued at $120.74 million, representing 5.96% of the adviser's U.S. equity assets. Spyre Therapeutics is a preclinical-stage biotech firm developing antibody-based treatments for inflammatory bowel diseases.
Signal or Noise: How VR Adviser's Acquisition of Spyre Therapeutics Impacts Fools
VR Adviser, LLC has significantly increased its stake in Spyre Therapeutics (NASDAQ: SYRE) by purchasing an additional 1,000,000 shares, valued at $25.78 million, making Spyre 5.96% of its AUM. Spyre Therapeutics is a preclinical-stage biotech developing treatments for inflammatory bowel disease, with its shares seeing a 132.1% increase over the past year. The article advises individual investors to consider their own risk tolerance before acting on such filings, given the speculative nature of preclinical biotech investments.
Spyre Therapeutics (SYRE) Is Up 7.3% After Accelerating SPY072 Phase 2 POC Timeline - Has The Bull Case Changed?
Spyre Therapeutics (SYRE) shares rose 7.3% after the company accelerated the timeline for its SPY072 Phase 2 proof-of-concept data for rheumatoid arthritis and other inflammatory diseases. This acceleration is due to the completion of recruitment for the RA sub-study and highlights the potential of basket trial designs to speed clinical learning. While this progress sharpens the near-term catalyst calendar, Spyre remains a pre-revenue biotech, and its valuation heavily depends on successful Phase 2 outcomes and ongoing execution in its SKYLINE-UC trial.
Leerink Maintains Outperform on Spyre Therapeutics, Inc. (SYRE) March 16, 2026
Leerink Partners has maintained an Outperform rating for Spyre Therapeutics, Inc. (SYRE) after its recent presentation at the Leerink Global Healthcare Conference, citing strong clinical execution. The rating, which did not include a new price target, led to a 0.94% intraday rise in SYRE shares. Investors are advised to consider upcoming trial milestones and the company's market capitalization, as clinical updates are expected to be the primary drivers for the stock's future movements.
BTIG Reiterates Buy Rating for Spyre Therapeutics (SYRE) with $70 Price Target | SYRE Stock News
BTIG analyst Julian Harrison has reiterated a Buy rating for Spyre Therapeutics (SYRE), maintaining a $70 price target. This decision reflects BTIG's ongoing confidence in the biotechnology company, which focuses on developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases. Wall Street analysts collectively project an average target price of $58.57 for SYRE, suggesting a 34.60% upside from its current price.
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
Spyre Therapeutics has announced the completion of recruitment for the rheumatoid arthritis (RA) sub-study of its SKYWAY basket trial and expects topline data by Q3 2026, an acceleration from previous projections. The company attributes this to high investigator enthusiasm and the unmet need for long-acting anti-TL1A antibodies in rheumatic diseases. This development positions Spyre to potentially advance to pivotal trials next year, with key data readouts from its IBD and rheumatic disease programs anticipated every quarter this year.
Spyre Therapeutics, Inc. $SYRE Shares Acquired by HighVista Strategies LLC
HighVista Strategies LLC significantly increased its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 91.3% in Q3, bringing its total to 215,746 shares valued at $3.62 million. Institutional investors now own approximately 80.39% of the company. Despite recent insider selling and a missed EPS estimate, analysts maintain a "Buy" rating with an average price target of $53.44, following several upgrades.
Baker BROS. Advisors LP Buys 373,297 Shares of Spyre Therapeutics, Inc. $SYRE
Baker BROS. Advisors LP significantly increased its stake in Spyre Therapeutics (NASDAQ:SYRE) by 59.6% in Q3, acquiring 373,297 shares to reach a total of 1,000,000 shares valued at approximately $16.76 million. Despite insider sales totaling $1.69 million over the past three months, institutional investors own 80.39% of the stock. Wall Street analysts currently rate SYRE as a "Buy" with an average price target of $53.44, amidst some mixed ratings.
DLD Asset Management LP Acquires New Position in Spyre Therapeutics, Inc. $SYRE
DLD Asset Management LP initiated a new position in Spyre Therapeutics (NASDAQ:SYRE) by purchasing 30,000 shares in Q3, valued at approximately $503,000. Other institutions like JPMorgan, Candriam, and Dimensional Fund Advisors significantly increased their holdings as well, bringing institutional ownership to about 80.39%. Despite recent insider selling and a Q3 EPS miss, analysts maintain largely bullish ratings with an average price target of $53.44.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, a clinical-stage biotechnology company, announced the grant of inducement stock options to two non-executive employees. These awards, totaling 46,600 shares, were approved by the independent Compensation Committee and were material to the employees' acceptance of employment with Spyre. The options have a 10-year term, an exercise price of $42.49, and vest over four years.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. announced the grant of inducement stock options to two non-executive employees to purchase 46,600 shares of common stock. These awards were approved by the independent Compensation Committee of the Board of Directors on March 2, 2026, and are material to the employees' acceptance of employment, aligning with Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term, an exercise price matching the closing stock price on March 2, 2026, and vest over a period tied to the employees' start dates and continuous service.
New Spyre hires get 46,600 stock options at $42.49 strike
Spyre Therapeutics announced it granted stock options for an aggregate of 46,600 shares to two new non-executive employees. The options, approved on March 2, 2026, have an exercise price of $42.49 per share and a 10-year term, with vesting commencing 25% after one year and then monthly thereafter. This move aligns with Nasdaq Listing Rule 5635(c)(4) and is part of Spyre's ongoing hiring and incentive strategy.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics announced the grant of inducement stock options to two non-executive employees to purchase an aggregate of 46,600 shares of common stock. These options were approved on March 2, 2026, with an exercise price of $42.49, and vest over a period subject to continuous service, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are part of the company's 2018 Equity Inducement Plan to attract and retain talent.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics announced the grant of stock options for an aggregate of 46,600 shares to two non-executive employees as equity inducement awards. These awards were approved on March 2, 2026, and are material to the employees' acceptance of employment, with an exercise price of $42.49 per share. The options will vest over four years, with a quarter vesting on the first anniversary of employment and the remainder monthly thereafter.
Spyre Therapeutics, Inc. $SYRE Shares Sold by TD Asset Management Inc
TD Asset Management Inc. has reduced its stake in Spyre Therapeutics (NASDAQ:SYRE) by 36.5% in the third quarter, selling 41,600 shares but still owning 72,368 shares valued at approximately $1.21 million. This sale represents about 0.12% of the company. Company insiders, including CEO Cameron Turtle and CFO Scott L. Burrows, have also been net sellers, offloading 47,500 shares in the past three months. Analysts currently hold a consensus "Buy" rating for SYRE, with an average target price of $53.44.
Scott Burrows Sells 2,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock
MarketBeat reports that Scott Burrows, CFO of Spyre Therapeutics (NASDAQ:SYRE), sold 2,500 shares of the company's stock on March 3rd for a total of $101,625. This sale reduced his position by 2.49%. Following the news, Spyre Therapeutics' shares dropped by 5.7% to $40.07, and the company's Q4 EPS missed analyst estimates.
Spyre Therapeutics CEO Sells 15,000 Shares
Spyre Therapeutics' CEO, Turtle Cameron, sold 15,000 shares of common stock on March 2, 2026, totaling $632,866. The sales were executed under a Rule 10b5-1 trading plan, with share prices ranging from $41.23 to $42.93. Following these transactions, Cameron directly owns 642,540 shares, including those subject to vesting.
Spyre Therapeutics (SYRE) CEO sells 15,000 shares in Rule 10b5-1 plan
Cameron Turtle, CEO of Spyre Therapeutics (SYRE), sold 15,000 shares of common stock on March 2, 2026, through a Rule 10b5-1 trading plan established on June 20, 2025. The sales were executed in two transactions at weighted average prices of $41.73 and $42.49 per share. Following these sales, the CEO directly holds 642,540 shares, including 130,683 shares that are subject to vesting through November 2026.
Spyre Therapeutics (SYRE) CFO sells 2,500 shares under 10b5-1 plan
Spyre Therapeutics CFO Scott L. Burrows exercised stock options for 2,500 shares and subsequently sold these shares in open-market transactions at weighted average prices of $40.56 and $41.66 under a pre-established Rule 10b5-1 trading plan. After these transactions, Burrows directly holds 97,994 shares, including 67,476 restricted stock units. The sales were reported in a Form 4 SEC filing on March 3, 2026.
Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $632,850.00 in Stock
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle sold 15,000 shares of company stock for $632,850 on March 2nd, reducing his stake by 2.28%. This sale follows similar transactions in February and January. The stock traded down 5.7% to $40.07 on Tuesday, missing quarterly EPS estimates, though analysts hold a "Buy" consensus rating with an average target price of $53.44.
SYRE Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Spyre Therapeutics (SYRE), including its income statement, balance sheet, cash flow statement, and key financial ratios through fiscal year 2025. It highlights the company's strong financial health score despite reporting no revenue and a net loss, attributed to efficient cost management and a low debt-to-equity ratio. The analysis also covers profitability, leverage, liquidity, and earnings quality, offering insights into its financial performance and outlining an estimated cash runway.
[EFFECT] Spyre Therapeutics, Inc. SEC Filing
This article reports on an SEC filing from Spyre Therapeutics, Inc. (NASDAQ: SYRE), specifically a Notice of Effectiveness for Form S-3. The filing, dated February 27, 2026, includes details such as the company's CIK and file number. The article also provides recent news and SEC filings related to Spyre Therapeutics, along with key stock data.
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Spyre Therapeutics, a clinical-stage biotechnology company, announced its participation in three investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference, the Leerink Global Healthcare Conference, and the Jefferies Biotech on the Beach Summit. Management will present at these events, focusing on their work in long-acting antibodies for inflammatory bowel disease and rheumatic diseases. Live audio webcasts and replays will be available on their investor relations website.
SYRE PE Ratio & Valuation, Is SYRE Overvalued
This article analyzes the valuation of Spyre Therapeutics Inc (SYRE), indicating it is currently in a "Fair zone" based on its forward PS ratio compared to its five-year average. It examines various financial metrics such as Price-to-Book ratio, Free Cash Flow yield, and compares SYRE's P/S ratio against its competitors, noting that its current P/S appears unsustainable despite robust revenue growth. The article also provides answers to frequently asked questions regarding SYRE's valuation and key financial ratios.
Spyre Therapeutics, Inc. targets breakthrough in inflammatory bowel disease with combination therapies
Spyre Therapeutics, Inc. is focusing on combination therapies to revolutionize inflammatory bowel disease treatment, aiming to overcome existing limitations. CEO Cameron Turtle is collaborating with leading gastroenterologists to advance these innovative strategies. The company positions itself at the forefront of improving care for patients with chronic gastrointestinal conditions.
Assessing Spyre Therapeutics (SYRE) Valuation After A Powerful Multi‑Period Share Price Run
Spyre Therapeutics (SYRE) has seen significant share price appreciation, with 30-day, year-to-date, and 1-year returns of 35.63%, 42.09%, and 110.41% respectively. The article examines the company's valuation using the Price-to-Book (P/B) ratio, noting its 6.1x P/B is below peers but above the broader US biotech average. It concludes that while the market seems to value Spyre's pipeline, risks associated with early-stage clinical data and losses remain.
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Spyre Therapeutics, a clinical-stage biotechnology company, announced its participation in three investor conferences in March 2026. The company's management will hold one-on-one meetings, and presentations will be available via live audio webcasts. Spyre is focused on developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases.
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Spyre Therapeutics, a clinical-stage biotechnology company, announced its participation in three investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference, the Leerink Global Healthcare Conference, and the Jefferies Biotech on the Beach Summit. Management will host one-on-one meetings, and webcasts of the presentations will be available. The company focuses on developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases.
Why Spyre Therapeutics (SYRE) Is Up 7.1% After Faster IBD Trial Timelines And New Commercial Chief
Spyre Therapeutics (SYRE) saw a 7.1% increase following announcements of accelerated trial timelines for its inflammatory bowel disease (IBD) pipeline, including six proof-of-concept readouts targeted for 2026 and earlier-than-expected enrollment completion for its SKYLINE trial. The company also appointed Kate Tansey Chevlen as Chief Commercial Officer, signaling a focus on commercial readiness alongside its advancing drug candidates SPY001 and SPY002. While these developments enhance the near-term catalyst profile, the article notes that fundamental risks related to funding, execution, and trial outcomes, as well as potential overvaluation, remain for investors.
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Spyre Therapeutics, a clinical-stage biotechnology company focused on inflammatory bowel disease and rheumatic diseases, announced its participation in three upcoming investor conferences in March 2026. Management will present at the TD Cowen 46th Annual Health Care Conference, and hold fireside chats and one-on-one meetings at the Leerink Global Healthcare Conference and Jefferies Biotech on the Beach Summit. Webcasts of these events will be available on the company's investor relations website.
